---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-055899"
form_type: "8-K"
ticker: "IRON"
cik: "0001816736"
company_name: "Disc Medicine, Inc."
filed_at: "2022-02-28T23:59:59+00:00"
generated_at: "2026-06-27T03:48:42.360081+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Gemini cuts workforce ~80%, initiates strategic review; CEO departs

## Summary
- Workforce reduction of 24 employees (approx. 80%) by end of Q2 2022; restructuring charge $1.6-1.9M in Q1 2022.
- CEO Jason Meyenburg departs; Executive Chair Georges Gemayel appointed interim President and CEO.
- Company initiates strategic alternatives review to maximize shareholder value; no timetable set.
- Remaining employees to focus on GEM307 IND-enabling tasks.
- Separation agreement includes 12 months base salary, pro-rata bonus, COBRA, and continued equity vesting.

## SEC filing metadata
- accession: 0001193125-22-055899
- form_type: 8-K
- ticker: IRON
- cik: 0001816736
- company_name: Disc Medicine, Inc.
- filed_at: 2022-02-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.05, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1816736/000119312522055899/0001193125-22-055899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1816736/000119312522055899/d29362d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-055899
- JSON: https://secwatch.observer/filing/0001193125-22-055899.json
- Plain text: https://secwatch.observer/filing/0001193125-22-055899.txt

## Key facts
- Executive change
  Jason Meyenburg resigned as President and Chief Executive Officer at Disc Medicine, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: Mr. Meyenburg’s last date of employment with the Company as its President and Chief Executive Officer is February 28, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312522055899/0001193125-22-055899-index.htm
- Executive change
  Georges Gemayel was appointed as Interim President and Chief Executive Officer at Disc Medicine, Inc..
  - Action: appointed
  - Role: Interim President and Chief Executive Officer
  source text: the Board appointed Dr. Georges Gemayel, the Company’s current Executive Chair, to serve as Interim President and Chief Executive Officer, effective as of February 28, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1816736/000119312522055899/0001193125-22-055899-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.